
Growth investor backing healthier-living food and drink brands, with advisors who are also investors

Boutique financial firm investing in and advising life sciences tools, diagnostics and biopharma services companies

From a boutique base in life sciences, BroadOak Capital Partners works in three sectors: life sciences tools, diagnostics and biopharma services. The firm provides direct investment through BroadOak Asset Management and investment banking through BroadOak Partners. It describes itself as the most active life sciences-focused boutique financial institution in its field, and it says its specialist knowledge sets it apart from general financial firms.
The investing arm offers growth capital to help established businesses develop and accelerate. The advisory arm helps management teams with sale processes, mergers, acquisitions and financing. The firm argues that these sectors are too specialized for most traditional financial institutions, and that a partner with real sector experience can offer a level of help that generalists cannot match.
BroadOak focuses on instruments and consumables used in the discovery and development of therapies, on diagnostic tests and the components and instruments used to analyse them, and on research, development and manufacturing services for biopharma companies. The firm says its in-house expertise, its relationships and its experience over more than twenty years give its portfolio companies and advisory clients results that exceed their expectations.
The firm reports more than 155 investments and transactions, eight investment funds raised and 41 portfolio exits. It says it has advised on more than 50 successful mergers and acquisitions and has invested in over 90 companies. These figures give an indication of how much of the sector's deal activity the firm has been part of, although the firm presents them as its own account of its record.
BroadOak names several companies it has worked with. Sanguine Biosciences supplies custom specimens to drug developers, which the firm says helps them speed up precision medicine work. CDI Laboratories offers biomarker discovery work based on serology, along with making and validating monoclonal antibodies. PBS Biotech makes single-use bioreactors and completed a financing round that the firm describes as part of its portfolio growth.
BroadOak Capital Partners is a boutique financial institution that specialises in life sciences. Since 2006 it has invested directly through BroadOak Asset Management and offered investment banking through BroadOak Partners.
Companies making research instruments and consumables, diagnostic tests and instruments, and research and manufacturing services for biopharma. It reports investments in over 50 companies and advice on over 50 mergers and acquisitions. Named deals include Sanguine Biosciences, CDI Laboratories and PBS Biotech.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
BroadOak Capital Partners is ranked on 1 TrustList ranking at #23.
Every ranking orders its listings by their reviews, how complete the profile is and the Trust Score. BroadOak Capital Partners has no reviews yet and 3 of the 10 profile details we look for. Where no listing on a page has been reviewed, the order follows the profiles alone.
It is the only one of the top 58 here listing banking and one of 2 here listing manufacturing.
Of the top 58 here, 13 also cover seed stage and 11 also cover growth stage; 23 also work in New York City and 18 also work in London.
As of 2026-11-16. Organic ranks only; sponsored placements are never ranks. How TrustList ranks
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about BroadOak Capital Partners.
Similar listings buyers compare against this one.

Growth investor backing healthier-living food and drink brands, with advisors who are also investors
Bank offering banking, cards and financial advice to founders, executives and investors in the innovation economy

Impact-focused venture firm investing in education and workforce technology companies that have proven solutions

Deep tech venture fund backing patent-based science startups in the US Southwest and Northern Europe

Capital and advisory firm for blockchain projects, part of Faculty Group

Austin venture capital firm backing early-stage applied AI companies across North America

Spanish venture capital manager investing in biotechnology and healthcare through life sciences funds

Private markets investment firm running buyout and infrastructure platforms focused on financial and business services
Everything here links back to the same verified catalogue. Pick your next stop.